NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.…
NFL Biosciences : recrutement du premier participant dans son étude de phase 2 TONIC et opération de...
NFL Biosciences (EPA: ALNFL) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 0.3380 EUR on 20 November 2026, down 63.3% over 52 weeks. Its 52-week range is 0.3105 EUR to 1.846 EUR: the price is 81.7% below the high and 8.9% above the low.
Its market capitalisation is 4.30M EUR.
Its Piotroski F-score is 0 out of 9, a weak reading of its financial health.
No upcoming events tracked.